Lesson plan

GemOx

GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma. When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R. The [R]-GemOx regimen consists of: # Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; # Gemcitabine - an antimetabolite; # Oxaliplatin - a platinum-based alkylating antineoplastic agent.

Back to article

Article summary

GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma. When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R. The [R]-GemOx regimen consists of: # Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; # Gemcitabine - an antimetabolite; # Oxaliplatin - a platinum-based alkylating antineoplastic agent.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.